ClinicalTrials.gg
CompletedNCT06453356Updated Oct 8, 2024

A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women

A Phase 1 interventional study of Zavegepant 10mg in Healthy, sponsored by Pfizer. Completed at 2 sites in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

The purpose of the study is to look at the amount of zavegepant that is present in breast milk after single dose of zavegepant is sprayed through the nose in healthy breast-feeding women. This would allow to see if there are any possible risk to infants from medicines during breast-feeding.

The study is seeking for about 12 healthy breast-feeding females who are:

  • 18 to 55 years of age.
  • actively breast-feeding or producing breast milk.
  • at least 2 weeks post-partum and not pregnant at present. Participants will not be allowed to breast-feed their infant from the evening of the day before to the first dose till 48 hours (2 days) after the dose.

Eligible participants will check into the clinical research unit (CRU) on Day -1. Participants will receive the zavegepant dose sprayed into the nose at the CRU on Day 1. The participants will stay at the CRU until the morning of Day 2. There will be collections of breast milk and plasma over 24 hours. Participants will be sent from the CRU on Day 2 and may begin to breastfeed their infant 48 hours (2 days) after the dose. A safety follow-up call will be done at about 28 to 35 days from the day the first dose of study medicine was given.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:

Age and Sex:

  1. Healthy lactating females who are actively breast-feeding or expressing breast milk, who are at least 2 weeks post-partum and not currently pregnant (must have a negative pregnancy test), and must be 18 to 55 years of age, inclusive, at the time of signing the Document (ICD).

    • Participants must be able to express at least 14 mL of breast milk over a 2-hour interval prior to the dose on Day 1.

    Other Inclusion Criteria:

  2. (BMI) 16.0-34.9 kg/m2 and body weight ≥45.0 kg (99 lb).
  3. Female participants with history of acute migraine are allowed.
  4. Participants must be willing to temporarily discontinue breastfeeding their infants for a total of 2.5 days (approximately 60 hours), ie, from the evening of the day before Day 1 through to 48 hours after the dose (approximately 8 AM the morning of Day 3). Participants must be willing to regularly pump breasts throughout the study and express breast milk according to a schedule designed to maintain lactation throughout the study period.
  5. Participants must agree that breast milk expressed following zavegepant administration through 48 hours after the dose should be discarded and will not be fed to any infant.

Exclusion criteria

-

Exclusion Criteria:

Participants with any of the following characteristics/conditions will be excluded:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological (with exception of acute migraine), or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  2. Clinically significant history of nasal conditions that may affect the administration or absorption of the nasal product (eg, severe septum deviation or nasal deformity, inflammation, perforation, mucosal erosion or ulceration, localized infection, congestion, polyposis, rhinorrhea, nasal surgery within the previous 6 months, or nasal trauma).
  3. Significant history of seizure disorder other than a single childhood febrile seizure (eg, epilepsy).
  4. History of gallstone or cholecystectomy.
  5. Any other medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to coronavirus disease 2019 (COVID-19) pandemic that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  6. Use of organic anion transporting polypeptide 1B3 (OATP1B3) inhibitors within 14 days or 5 half-lives, whichever is longer, before first dosing.
  7. Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to investigational product (IP) dosing, administration of a biological product in the context of a clinical research study within 90 days prior to IP dosing, or concomitant participation in an investigational study involving no drug or device administration.
  8. Any clinically significant abnormal laboratory test results or positive test found during medical screening. A single repeat for positive drug screen may be allowed at the discretion of the principal investigator (PI).
  9. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination or nasal inspection beyond what is consistent with the target population.
  10. Participants with ANY of the following abnormalities in clinical laboratory tests at screening:

    • (AST) or alanine aminotransferase (ALT) level > 1.5 × (ULN);
    • Total level >1.5 × ULN;
    • Estimated (eGFR) of \<60 mL/min/1.73m².
  11. Individuals who smoke more than 5 cigarettes or equivalent daily.
  12. Presence of piercings or any physical findings in the nose that, in the opinion of the PI, would likely interfere with the successful completion of the dosing procedure.
  13. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
  14. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit, or 3 ounces (90 mL) of wine).
  15. Any reason that, in the opinion of the PI, would prevent the participant from participating in the study.

    -

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Zavegepant 10mg

    Intranasal (IN) 10mg spray on Day 1

    Drug: Zavegepant 10mg

Interventions

  • intransal spray 10mg

    Also known as: Zavzpret, PF-07930207

06

What researchers measure

Primary outcomes

  1. Area Under the Breast Milk Concentration-time Profile from time 0 extrapolated to infinite time (AUCinf), if data permit

    AUCinf = Area under the breast milk concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).

    Time frame: 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 16, 16 to 24 hours

  2. Area Under the Breast Milk Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast)

    Area under the breast milk concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 16, 16 to 24 hours

  3. Area Under the Breast Milk Concentration-time Profile From Time Zero to the Time of 24 hr post dose (AUC24)

    AUC24= Area under the breast milk concentration versus time curve from time zero (pre-dose) to time 24 hours

    Time frame: 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 16, 16 to 24 hours

  4. Maximum observed breast milk concentration (Cmax)

    Time frame: 0 to 24 hours post dose

  5. Time for Cmax in Breast Milk (Tmax)

    Time frame: 0 to 24 hours post dose

  6. Terminal half-life for breast milk (t 1/2), if data permit

    Time frame: 0 to 24 hours post dose

Secondary outcomes

  1. Area under the concentration-time profile from time 0 extrapolated to infinite time (AUCinf), if data permit

    AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).

    Time frame: 0 to 24 hours post dose

  2. Area under the concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: 0 to 24 hours post dose

  3. Area under the concentration-time profile from time 0 to 24 hours post dose (AUC24)

    AUC24= Area under the plasma concentration versus time curve from time zero (pre-dose) to time 24 hours

    Time frame: 0 to 24 hours post dose

  4. Maximum observed plasma concentration (Cmax)

    Time frame: 0 to 24 hours post dose

  5. Time for plasma Cmax (Tmax)

    Time frame: 0 to 24 hours post dose

  6. Plasma Terminal half-life (t 1/2), if data permit

    Time frame: 0 to 24 hours post dose

  7. Average plasma concentration (Cav) over 24 hr

    Time frame: 0 to 24 hours post dose

  8. Breast milk to plasma ratio for AUCinf (MPAUCinf), if data permit

    Time frame: 0 to 24 hours post dose

  9. Breast milk to plasma ratio (MPAUC24) for AUC24, if data permit

    Time frame: 0 to 24 hours post dose

  10. Breast milk to plasma ratio for Cmax (MPCmax)

    Time frame: 0 to 24 hours post dose

  11. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to at least 28 days after last dose of study drug

  12. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Time frame: 0 to 24 hours post dose

  13. Number of Participants With Clinically Significant Change from Baseline in Electrocardiogram (ECG) Parameters

    Time frame: 0 to 24 hours post dose

  14. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: 0 to 24 hours post dose

07

Study locations

2 sites
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO
    Springfield, Missouri 65802, United States
  • Bio-Kinetic Clinicals Applications LLC DBA QPS-MO Patient Screening and Recruitment Center Center)
    Springfield, Missouri 65807, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Sep 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 11, 2024
StartActual
Jun 10, 2024
Primary completionActual
Sep 26, 2024
CompletionActual
Sep 26, 2024
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06453356
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 11, 2024
Start date
Jun 10, 2024
Primary completion
Sep 26, 2024
Completion
Sep 26, 2024
Last update
Oct 8, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion